FY2025 EPS Estimates for Ironwood Pharmaceuticals, Inc. Raised by Analyst (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Capital One Financial boosted their FY2025 earnings estimates for Ironwood Pharmaceuticals in a report issued on Wednesday, May 1st. Capital One Financial analyst T. Chiang now expects that the biotechnology company will earn $0.88 per share for the year, up from their prior forecast of $0.85. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.71 per share.

Several other brokerages also recently commented on IRWD. Craig Hallum initiated coverage on Ironwood Pharmaceuticals in a research report on Wednesday, January 17th. They issued a "buy" rating and a $21.00 price objective on the stock. StockNews.com lowered Ironwood Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, April 6th. Piper Sandler upped their price target on shares of Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Friday, February 16th. Finally, Wells Fargo & Company reduced their target price on shares of Ironwood Pharmaceuticals from $20.00 to $14.00 and set an "overweight" rating on the stock in a report on Friday, March 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $19.80.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ:IRWD traded down $0.18 during midday trading on Friday, hitting $8.12. The company had a trading volume of 1,863,455 shares, compared to its average volume of 4,250,431. The company has a fifty day moving average of $8.82 and a two-hundred day moving average of $10.60. Ironwood Pharmaceuticals has a 12-month low of $7.53 and a 12-month high of $15.70. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -1.25 and a beta of 0.57.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Xponance Inc. bought a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at about $144,000. GW Henssler & Associates Ltd. acquired a new stake in Ironwood Pharmaceuticals in the third quarter valued at approximately $186,000. Mackenzie Financial Corp grew its holdings in Ironwood Pharmaceuticals by 21.5% in the third quarter. Mackenzie Financial Corp now owns 12,713 shares of the biotechnology company's stock worth $123,000 after purchasing an additional 2,253 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Ironwood Pharmaceuticals by 3.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 91,060 shares of the biotechnology company's stock worth $877,000 after purchasing an additional 3,460 shares in the last quarter. Finally, Inspire Investing LLC increased its position in shares of Ironwood Pharmaceuticals by 7.8% during the third quarter. Inspire Investing LLC now owns 31,669 shares of the biotechnology company's stock worth $305,000 after purchasing an additional 2,294 shares in the last quarter.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 177,164 shares of the business's stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $15.24, for a total transaction of $2,699,979.36. Following the completion of the transaction, the chief executive officer now owns 832,774 shares in the company, valued at $12,691,475.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Andrew Davis sold 9,846 shares of the company's stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $15.24, for a total value of $150,053.04. Following the completion of the sale, the senior vice president now directly owns 208,324 shares of the company's stock, valued at $3,174,857.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas A. Mccourt sold 177,164 shares of the firm's stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $2,699,979.36. Following the transaction, the chief executive officer now directly owns 832,774 shares in the company, valued at approximately $12,691,475.76. The disclosure for this sale can be found here. Insiders have sold 273,008 shares of company stock valued at $4,160,642 in the last ninety days. 13.10% of the stock is owned by company insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.